CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.
As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
i
Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019
-
January 10 2020
-
-
Source: MMWR Morbidity Mortal Weekly Rep. 69(1):6-9
[PDF-147.48 KB]
Details:
-
Journal Article:Morbidity and Mortality Weekly Report (MMWR)
-
Personal Author:
-
Corporate Authors:
-
Description:Candida auris is a globally emerging yeast that causes outbreaks in health care settings and is often resistant to one or more classes of antifungal medications (1). Cases of C. auris with resistance to all three classes of commonly prescribed antifungal drugs (pan-resistance) have been reported in multiple countries (1). C. auris has been identified in the United States since 2016; the largest number (427 of 911 [47%]) of confirmed clinical cases reported as of October 31, 2019, have been reported in New York, where C. auris was first detected in July 2016 (1,2). As of June 28, 2019, a total of 801 patients with C. auris were identified in New York, based on clinical cultures or swabs of skin or nares obtained to detect asymptomatic colonization (3). Among these patients, three were found to have pan-resistant C. auris that developed after receipt of antifungal medications, including echinocandins, a class of drugs that targets the fungal cell wall. All three patients had multiple comorbidities and no known recent domestic or foreign travel. Although extensive investigations failed to document Transmission of pan-resistant isolates from the three patients to other patients or the environment, the emergence of pan-resistance is concerning. The occurrence of these cases underscores the public health importance of Surveillance for C. auris, the need for prudent antifungal prescribing, and the importance of conducting susceptibility tTesting on all clinical isolates, including serial isolates from individual patients, especially those treated with echinocandin medications. This report summarizes investigations related to the three New York patients with pan-resistant infections and the subsequent actions conducted by the New York State Department of Health and hospital and long-term care facility partners.
-
Subjects:
-
Source:
-
Series:
-
ISSN:0149-2195 (print);1545-861X (digital);
-
Pubmed ID:31917780
-
Pubmed Central ID:PMC6973342
-
Document Type:
-
Place as Subject:
-
Pages in Document:4 pdf pages
-
Volume:69
-
Issue:1
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
